

Is Automated Insulin Delivery System Therapy Safe and Effective in Children Under Seven Years Old?

İ Nihal Gül Uslu, İ Deniz Özalp Kızılay, İ Günay Demir, İ Yasemin Atik Altınok, İ Şükran Darcan, İ Samim Özen, İ Damla Gökşen

Ege University Faculty of Medicine, Department of Pediatrics, Clinic of Pediatric Endocrinology, İzmir, Türkiye

What is already known on this topic?

The evidence, experience and knowledge about the use of automated insulin delivery systems in patients under seven years of age are currently inadequate.

What this study adds?

The present study demonstrated for the first time that the MiniMed™ 780G may be used in patients with type 1 diabetes mellitus under seven years of age by comparing the MiniMed™ 780G with the MiniMed™ 640G and multiple daily dose therapy.

Abstract

Objective: To evaluate the off-label use of the MiniMed™ 780G system in children under seven years old, as clinical outcomes in this age group are less well-established, despite the improvements in glycemic control seen with MiniMed™ 780G therapy.

Methods: Children under seven years old with type 1 diabetes using MiniMed™ 780G pump therapy were compared with children of similar age and gender using MiniMed™ 640G insulin pump therapy and multiple-dose insulin therapy with continuous glucose monitoring systems (CGMs). CGM metrics, total daily insulin (TDI) dose, and hemoglobin A1c (HbA1c) levels were evaluated retrospectively at baseline and at the 3rd, 6th, and 12th months.

Results: At the initiation of MiniMed™ 780G therapy, the mean age was 5.25 ± 1.22 years (range: 2.8-6.8 years), and the mean TDI was 10.12 ± 4.34 U/day (range: 4.5-17.0 U/day). The glucose management indicator and HbA1c remained lower in the MiniMed™ 780G group at the 3rd, 6th, and 12th months compared to baseline ($p = 0.009$ and $p < 0.001$, respectively). In the MiniMed™ 780G group, time above range (TAR) was significantly lower at the 3rd, 6th, and 12th months ($p = 0.018$, $p = 0.017$ and $p = 0.04$, respectively) while time in range (TIR) was higher at the 3rd, and 12th months ($p = 0.026$ and $p = 0.019$, respectively) compared to other groups. The coefficient of variation (CV) of the sensor glucose and HbA1c were lower at the 12th month ($p = 0.008$ and $p = 0.015$, respectively) compared to both other groups. No instances of ketoacidosis or severe hypoglycemic events were observed in any of the children during the follow-up period.

Conclusion: The absence of significantly higher levels of hypoglycemia compared to other groups at any time point, along with a significant decrease in TAR across all time points, a significant increase in TIR at the 3rd and 12th months, and a significant decrease in HbA1c and CV suggests that the MiniMed™ 780G system is both safe and effective for children under seven years old.

Keywords: Automated delivery system, diabetes, diabetes mellitus, endocrinology, predictive low glucose suspension

Cite this article as: Uslu NG, Özalp Kızılay D, Demir G, Atik Altınok Y, Darcan Ş, Özen S, Gökşen D. Is automated insulin delivery system therapy safe and effective in children under seven years old?. J Clin Res Pediatr Endocrinol. 2025;17(2):153-160



Address for Correspondence: Nihal Gül Uslu MD, Ege University Faculty of Medicine, Department of Pediatrics, Clinic of Pediatric Endocrinology, İzmir, Türkiye
E-mail: nihalgul87@gmail.com **ORCID:** orcid.org/0009-0003-9091-4032

Received: 04.11.2024

Accepted: 19.11.2024

Epub: 20.11.2024

Publication date: 27.05.2025



©Copyright 2025 by Turkish Society for Pediatric Endocrinology and Diabetes / The Journal of Clinical Research in Pediatric Endocrinology published by Galenos Publishing House.
 Licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 (CC BY-NC-ND) International License.

Introduction

The incidence of type 1 diabetes (T1D) continues to rise, with 18% of new diagnoses occurring in children aged nine and younger (1). Treatment of T1D in young children is challenging since they often experience marked day-to-day and within-day variability in glucose levels and high variability in insulin requirements compared with older children with T1D (2). Current glycemic goals issued by the American Diabetes Association and the International Society of Pediatric and Adolescent Diabetes (ISPAD) recommend that young children maintain a hemoglobin A1c (HbA1c) level <7.0% when possible but without risk of severe hypoglycemia (3). However, recent data from the SWEET study found that 69% of children with T1D under six years old have HbA1c higher than 7%, suggesting this age group would benefit from increased attention and interventions to support diabetes management (4). Diabetes management is complicated by rapid physical and neurological development, difficulty verbalizing thoughts and feelings, frequent and unpredictable physical activity, picky eating, and behavioral challenges and fears (5). The fear of nighttime hypoglycemia is common, and only a minority of young children's hypoglycemia appears to be recognized with self-monitoring blood glucose (BG) measurements (6). Apart from hypoglycemia, a 6-year longitudinal study suggested that gray and white matter volumes and cognitive scores are affected by hyperglycemia in early-onset T1D (7).

Diabetes technology, insulin pumps, and continuous glucose monitoring systems (CGMs) are evolving tools for diabetes management, and the use of such technologies in young children has increased markedly in recent years (8). Recent data from the T1D exchange indicate that CGM use in children under 6 years old has increased by 45% from 2016 to 2022 (9), and insulin pump use nearly doubled, with the highest use rates in the youngest patients (10). Hybrid closed-loop systems, which automatically adjust insulin delivery according to glucose levels aside from mealtime boluses, are relatively novel in young children. There are results from observational and randomized studies for MiniMed™ 780G systems in children over seven years old suggesting that an algorithm that automatically doses basal insulin based on sensor glucose (SG) levels improved time in range (TIR) without increasing or even decreasing the time spent below range (TBR) (11,12,13). Use of the MiniMed™ 780G improved glycemic control safely in a 12-week study period in toddlers and preschoolers, while simultaneously diminishing parental diabetes distress (14). In another study involving 11 patients aged between 2 and 6 years, the use of MiniMed™ 780G for 6 months resulted in an increase in TIR without any risk of hypoglycemia (15).

This is the first safety study comparing the off-label use of MiniMed™ 780G in children aged 2-7 years, diagnosed with T1D for at least one year and comparing with in patients using MiniMed™ 640G pump or multiple daily insulin (MDI) therapy plus CGM and comparing outcomes quarterly over a period of one year.

Methods

This retrospective, non-randomised study reviewed children between 2 and 7 years of age diagnosed with T1D for at least one year and who were on MiniMed™ 780G insulin pump, MiniMed™ 640G insulin pump or MDI + CGM therapy at least 12 months. HbA1c, insulin dose and CGM metrics of all the patients were downloaded from patient charts and Medtronic Carelink Personal Software, Libreview, and Dexcom Clarity Diabetes Management Software reports retrospectively. Clinicians and diabetes nurses monitored the safety of the treatment on a weekly basis (via phone call and WhatsApp), and pump settings [target glucose, insulin carbohydrate ratio, active insulin time (AIT)] were adjusted as required in the first month of pump initiation and monthly thereafter.

In our T1D clinic, all patients receive standardized training. T1D patients who start on MiniMed™ 780G or MiniMed™ 640G pump therapy receive complete carbohydrate counting training standardised according to ISPAD guidelines (16,17). In patients under 7 years of age the MiniMed™ 780G insulin pump is initially used in manual mode for 2 weeks followed by auto mode. The target BG is set to 100 mg/dL, and the active insulin time to 3 hours initially.

In MiniMed™ 640G insulin pump therapy, target BG is set to 100 mg/dL, low glucose suspend to 60 mg/dL, low and high alarm to 60 mg/dL and 180 mg/dL, and active insulin time to 3 hours at the beginning.

MDI + CGM patients receive the standardised education for CGM including the use of arrows, alarm settings and target glucose levels according to the CGMs consensus (18).

Outcomes measured included CGMs metrics according to the international recommendations (19). Safety endpoints included serious adverse events, such as severe hypoglycemia and diabetic ketoacidosis. Clinical and glycemic data are reported using descriptive statistics, expressed as mean (standard deviation) and/or median (interquartile range).

Ethical committee approval was obtained from the Ethics Committee of the Ege University (decision date: 24-5.1T/24, date: 23.05.2024). The study was conducted in accordance with the Helsinki Declaration, which was revised in October

2013. Informed consent was obtained from all parents or caregivers of children recruited in the study.

Statistical Analysis

Statistical Package for the Social Sciences statistics for Windows, version 28.0. was used for statistical analysis (IBM Inc., Armonk, NY, USA). A normality test was performed for the distribution. Shapiro-Wilk test was used in groups that included 30 or fewer children; otherwise, Kolmogorov-Smirnov test was used to determine distribution. One-way ANOVA test was used to compare MiniMed™ 780G, MiniMed™ 640G, and MDI+CGMs therapy groups in normally distributed variables. Kruskal-Wallis test was used to compare three groups' variables which were not distributed normally. Wilcoxon test was used in variables that were not distributed normally to compare pre-treatment (baseline) variables with the same at 3, 6 and 12 months. These were TAR, TIR, TBR, HbA1c, and other variables in the same group, and a paired t-test was used as a parametric equivalent. A $p < 0.05$ was accepted as statistically significant.

Results

Thirty-three children with T1D, eleven using the MiniMed™ 780G insulin pump, eleven MiniMed™ 640G insulin pump, and eleven using MDI+CGMs, were retrospectively analyzed. Among the 33 participants, 14 (42%) were

female, the mean age was 98 ± 1.39 (2-6,8) years at the time of CGMs/pump initiation, and the duration of diabetes was 3.51 ± 1.54 years.

The mean age at the initiation of the MiniMed™ 780G, MiniMed™ 640G insulin pump was 5.25 ± 1.22 (2.8-6.8) years and 4.1 ± 2.13 (2.0-6.5) years, respectively. In the MDI+CGMs group, the mean age was 5.59 ± 1.19 (3.3-6.7) years.

In the MiniMed™ 780G group, SmartGuard™ usage in all children exceeded 85% after the initial two weeks of use in manual mode, as intended (93.73%, 96.45%, and 87.91% at 3, 6 and 12 months, respectively). The glucose management indicator (GMI) and HbA1c remained significantly lower within this group over time ($p = 0.01$ and $p < 0.001$, respectively); of note, marked decreases were observed within three months after auto-mode was switched on (Table 1).

Initially mean TDI dose was 10.6 ± 4.34 (4.5-17.6) U/day in the MiniMed™ 780G group, 13.9 ± 6.0 (3.5-24.2) in the MiniMed™ 640G group, and 14.8 ± 6.72 (4.5-25.0) in the MDI+CGMs group. In the MiniMed™ 780G group, TAR was lower at the 3rd, 6th, and 12th months ($p = 0.02$, $p = 0.02$ and $p = 0.04$, respectively) while TIR was higher at the 3rd and 12th months ($p = 0.03$ and $p = 0.02$, respectively). TIR increased by 8.4% (70% to 75.9%), TAR decreased by 10.4% (23.67% to 21.2%), and TBR decreased by 12.1% (3.3% to 2.9%) in twelve months of MiniMed™ 780G use

Table 1. Comparison between 0-3-6-12. month values extracted from MiniMed™ 780G

	MiniMed™ 780G				p
	0. month initiation "Manuel Mode"	3. month	6. month	12. month	
TAR (%)	23.67 ± 12.72	18.44 ± 7.33	20 ± 5.92	21.2 ± 8.93	0.91
180-250	17.64 ± 7.02	15.91 ± 5.13	17.18 ± 6.1	18.09 ± 5.43	0.56
> 250	4.73 ± 6.77	3.55 ± 2.70	6.82 ± 11.5	3.55 ± 3.39	0.41
TIR (%)	$70.00 \pm 16.01^{**}$	$76.67 \pm 7.11^{**}$	72.45 ± 15.61	75.90 ± 7.71	0.891
TBR (%)	4.67 ± 3.14	4.78 ± 2.86	3.64 ± 2.42	5.46 ± 2.13	0.27
54-70	2.82 ± 2.4	3.27 ± 2.01	2.91 ± 1.81	2.45 ± 1.29	0.50
< 54	0.45 ± 0.69	1.27 ± 2.1	0.64 ± 0.81	0.45 ± 0.52	0.42
CV (%)	36.13 ± 5.62	37.13 ± 4.35	36.46 ± 3.58	34.3 ± 2.14	0.38
GMI (%)	7.27 ± 1.19	6.56 ± 0.22	6.64 ± 0.21	6.71 ± 0.38	0.01
HbA1c (%)	8.8 ± 1.7	6.64 ± 0.47	6.71 ± 0.4	6.51 ± 0.38	< 0.001
SmartGuard™ (%)	-	93.73 ± 12.96	96.45 ± 3.45	87.91 ± 29.3	
TDI (U/day) (min-max)	4.5-17.6	8.2-20.3	7.7-25.9	9.3-33.2	0.08
AIT (hours)	3	3	3	3	
Meal per day	4.4 ± 1.1	4.8 ± 2	5.9 ± 1.4	6.1 ± 2.1	0.08
Amount of carb	128.6 ± 33.5	136.1 ± 45.4	154.8 ± 28.6	154.5 ± 33.2	0.09

Significant difference regarding GMI and HbA1c was observed during the one-year follow-up. The most remarkable improvement was between 0 to 3 months.

**Although TIR didn't show any significant increase when 12 months statistically examined together. It was significantly changed between initial time to 3rd month ($p < 0.001$).

AIT: active insulin time, CGMs: continuous glucose monitoring system, CV: coefficient of variation, GMI: glucose management indicator, MDI: multiple dose insulin treatment, TAR: time above range, TBR: time below range, TDI: total daily insulin dose, TIR: time in range, HbA1c: hemoglobin A1c, min-max: minimum-maximum

(Figure 1). The coefficient of variation (CV) of the SG and HbA1c were lower at 12 months ($p=0.01$ and $p=0.02$, respectively) (Figure 2). Moreover, average BG was lower at the 6th and 12th months ($p=0.02$ and $p=0.01$, respectively) compared to the other groups (Table 2). The other MiniMed™ 780G, MiniMed™ 640G, and CGM data are also shown in Table 2.

Discussion

T1D is associated with numerous morbidities that may significantly impact the lives of children. Initiating the most effective therapy as early as possible can mitigate complications (20). The MiniMed™ 780G insulin pump appears to be the most effective therapy for achieving this goal (21). However, there is a notable lack of studies investigating the effectiveness and safety of such devices




Figure 1. TIR, TAR, and TBR changes of the groups

780G: minimed™ 780G, 640G: minimed™ 640G, MDI + CGM: multiple dose insulin + continuous glucose monitoring, TAR: time above range, TBR: time below range, TIR: time in range




Figure 2. HbA1c and CV changes of the groups

780G: minimed™ 780G, 640G: minimed™ 640G, CV: coefficient of variation, MDI + CGM: multiple dose insulin + continuous glucose monitoring, HbA1c: hemoglobin A1c

Table 2. Comparison between MiniMed™ 780G and MiniMed™ 640G and CGMs + multi-dose SC insulin users

	0-month			p*	3-month		
	MiniMed™ 780G	MiniMed™ 640G	MDI + CGMs		MiniMed™ 780G	MiniMed™ 640G	MDI + CGMs
TAR (%)	23.7 ± 12.7	32.4 ± 12.7	33.6 ± 19.8	0.11	18.4 ± 7.3	36.5 ± 17.9	34.3 ± 15.5
180-250	17.6 ± 7	25.6 ± 10.5	21.6 ± 9.5	0.14	15.9 ± 5.1	28.1 ± 14.4	25.5 ± 7.6
> 250	4.7 ± 6.8	6.8 ± 5.3	12.3 ± 11.7	0.11	3.6 ± 2.7	8.4 ± 5.8	8.6 ± 8.8
TIR (%)	70 ± 16	63.8 ± 13.8	64.7 ± 19.7	0.24	76.7 ± 7.1	59.6 ± 17.5	63.6 ± 15.1
TBR (%)	4.7 ± 3.1	3.8 ± 2.4	1.6 ± 1.1	0.06	4.8 ± 2.9	3.7 ± 2.8	2.4 ± 2.3
54-70	2.8 ± 2.4	3.1 ± 1.9	2.4 ± 2.5	0.75	3.3 ± 2	3.1 ± 2.3	2.3 ± 2.1
< 54	0.5 ± 0.7	0.7 ± 0.8	0	0.03*	1.3 ± 2.1	0.6 ± 0.9	0.1 ± 0.3
CV (%)	36.1 ± 5.6	36.4 ± 5.3	36.3 ± 5.5	0.98	37.1 ± 4.4	35.4 ± 5.7	34.8 ± 5.1
GMI (%)	7.3 ± 1.2	6.4 ± 2.2	5.2 ± 3.4	0.15	6.6 ± 0.2	7.1 ± 6.4	6.4 ± 2.4
HbA1c (%)	8.8 ± 1.7	7.5 ± 1.1	7.5 ± 1.3	0.22	6.6 ± 0.5	7.2 ± 0.8	7.2 ± 1.3
Average BG (mg/dL)	161.3 ± 25.8	166.4 ± 27.6	-	0.91	152.4 ± 24.5	173.7 ± 27.9	-
TDI (U/day) (min-max)	10.6 (4.5-17.6)	13.9 (3.5-24.2)	14.8 (4.5-25)	0.25	12.8 (8.2-20.3)	15.1 (4-25.6)	15.7 (5-26)
Amount of bolus insulin (U)	6.7 ± 2.9	9.2 ± 4.5	-	0.18	8 ± 2	10.4 ± 4.9	-
Auto-correction insulin (U)	-	-	-	-	1.1 ± 0.9	-	-
Basal insulin (U)	4 ± 2.7	4.2 ± 2	-	0.55	4.8 ± 3	4.5 ± 2.4	-
Meal per day	4.4 ± 1.1	6.6 ± 1.9	-	0.01*	4.8 ± 2	5.9 ± 1.2	-
Amount of carb	128.6 ± 33.5	144.9 ± 38.2	-	0.28	136.1 ± 45.4	143.7 ± 42.9	-
Average SG (mg/dL)	145.1 ± 20	153.7 ± 15.1	162.7 ± 32.4	0.27	139.8 ± 13	158.5 ± 21.1	161.7 ± 23.6

Table 2. Continued

	p*	6-month			p*	12-month			p*
		MiniMed™ 780G	MiniMed™ 640G	MDI + CGMs		MiniMed™ 780G	MiniMed™ 640G	MDI + CGMs	
TAR (%)	0.02*	20 ± 5.9	39 ± 18.7	36.6 ± 19.4	0.02*	21.2 ± 8.9	31.3 ± 10.7	37.2 ± 19.4	0.04*
180-250	0.02*	17.2 ± 6.1	28.7 ± 13.7	25.1 ± 11.3	0.05	18.1 ± 5.4	23.5 ± 6.8	20.7 ± 6.6	0.15
> 250	0.12	6.8 ± 11.5	10.3 ± 7.7	11.5 ± 11.7	0.56	3.6 ± 3.4	7.82 ± 4.22	16.5 ± 18.5	0.03*
TIR (%)	0.03*	72.5 ± 15.6	57.3 ± 17.9	60.5 ± 19.1	0.12	75.9 ± 7.7	64.7 ± 9.7	59.1 ± 18.7	0.02*
TBR (%)	0.18	3.6 ± 2.4	3.7 ± 2.6	3 ± 2.2	0.75	5.5 ± 2.1	4 ± 3.1	3.7 ± 3	0.94
54-70	0.51	2.9 ± 1.8	3 ± 1.8	2.9 ± 2.2	0.99	2.5 ± 1.3	3.2 ± 1.9	3.6 ± 2.9	0.48
< 54	0.13	0.6 ± 0.8	0.7 ± 0.9	0.1 ± 0.3	0.1	0.5 ± 0.5	0.8 ± 1.5	0.2 ± 0.4	0.29
CV (%)	0.7	36.5 ± 3.6	36.5 ± 5.4	35.8 ± 5.5	0.92	34.3 ± 2.1	37 ± 3.8	39.7 ± 4.9	0.01*
GMI (%)	0.47	6.6 ± 0.2	7.3 ± 0.5	6.6 ± 2.3	0.46	6.7 ± 0.4	6.1 ± 2.1	6.5 ± 2.2	0.63
HbA1c (%)	0.68	6.7 ± 0.4	7.3 ± 0.7	7.6 ± 1.6	0.18	6.5 ± 0.4	7.4 ± 0.5	7.6 ± 1.3	0.02*
Average BG (mg/dL)	0.16	151.6 ± 30.7	180.9 ± 21.9	-	0.02*	152.5 ± 28.2	179.6 ± 14.6	-	0.01*
TDI (U/day) (min-max)	0.55	13.9 (7.7-25.9)	16 (6.2-24.9)	18.9 (5.2-22)	0.2	15.9 (9.3-33.2)	17.6 (5.8-29.4)	21.4 (13-34)	0.26
Amount of bolus insulin (U)	0.28	8.8 ± 2.3	11 ± 4.2	-	0.18	9.9 ± 2.8	11.8 ± 5.1	-	0.39
Auto-correction insulin (U)	-	2.1 ± 1.6	-	-	-	2.6 ± 2.2	-	-	-
Basal insulin (U)	0.97	5.1 ± 2.9	5 ± 2.3	-	0.53	6.1 ± 4.1	5.9 ± 2.2	-	0.55
Meal per day	0.12	5.9 ± 1.4	6.1 ± 1.7	-	0.97	6.1 ± 2.1	5.9 ± 1.5	-	0.77
Amount of carb	0.62	154.8 ± 28.6	149.2 ± 35.7	-	0.6	154.5 ± 33.2	158.6 ± 38.8	-	0.67
Average SG (mg/dL)	0.78	141.3 ± 13.7	164.7 ± 22.4	163.5 ± 29	0.02*	142.6 ± 14.2	156.9 ± 16.3	169.6 ± 42.9	0.83

*p < 0.05: Statistically significant.

BG: blood glucose, carb: carbohydrate, CGMs: continuous glucose monitoring system, CV: coefficient of variation, GMI: glucose management indicator, SC: subcutaneous, SG: sensor glucose, MDI: multiple dose insulin treatment, TAR: time above range, TBR: time below range, TDI: total daily insulin dose, TIR: time in range, HbA1c: hemoglobin A1c, min-max: minimum-maximum

in children under seven years old. Additionally, glucose control in this age group is challenging due to the variability of insulin requirements (2). This paper aimed to show the effectiveness and reliability of the MiniMed™ 780G insulin pump in children aged 2 to 7 years.

Pulkkinen et al. (14) investigated 35 children aged between 2 to 6 years old receiving MiniMed™ 780G treatment. In their study, TIR showed an 8.3% increase with an 8.6% decrease in TAR during the 12 weeks under MiniMed™ 780G treatment. Similar results were reported in their extended follow-up study, though they focused on time in tight range. TIR increased from 58.3% initially to 66.2% in the sixth month, and these values were sustained during an 18-month follow-up. However, TIR remained below 70% throughout the investigation, with the most significant increase observed in the first three months. They concluded that TIR values below 70% might be attributable to the younger age group and lower baseline TIR values compared to other studies (22). Tornese et al. (23) also investigated MiniMed™ 780G in a similar age group, showing an 8.5% increase in TIR along with a significant decrease in TAR. A further study conducted by Abraham et al. (15) found that TIR increased from 64.1% at baseline to 74.7% in the fifth week. In our study, similar to the aforementioned studies, TIR increased by 6.67% in the third month, which remained consistent throughout the 12 months. It demonstrated statistically significantly higher values than the MiniMed™ 640G and MDI + CGMs groups in the third and sixth months, and this difference persisted during the follow-up period.

TAR and TBR serve as additional indicators of treatment success. Similar to studies conducted by Pulkkinen et al. (22) and Tornese et al. (23), TAR showed a significant decrease during follow-up in our study. Additionally, TAR was significantly lower than in the other treatment groups, except initially. However, TBR did not significantly decrease in MiniMed™ 780G compared to MiniMed™ 640G and MDI + CGMs. Furthermore, no instances of severe hypoglycemia or ketoacidosis were observed in any case. This suggests that the MiniMed™ 780G insulin pump is as safe as the MiniMed™ 640G insulin pump and MDI + CGMs, as indicated by TBR and TAR in this vulnerable age group.

Pulkkinen et al. (22) showed that CV didn't decrease significantly during the follow-up period. In contrast to Pulkkinen et al. (22), Tornese et al. (23) found a significant decrease in CV during their study period. Our study is the first study that compares CV between three different treatment groups. Similar to Pulkkinen et al. (22), CV didn't change during the follow-up in our research but was significantly lower in the MiniMed™ 780G group compared to the other treatment groups.

Pulkkinen et al. (22) found that HbA1c decreased significantly over 18 months. However, during the follow-up period, they observed a temporary increase in HbA1c between the sixth and twelfth months, which was attributed to the lifting of COVID-19 restrictions, particularly an increase in infections during that period. In our study, HbA1c decreased significantly during the 12-month follow-up in the MiniMed™ 780G group. It was significantly lower in the MiniMed™ 780G group, with the most remarkable change observed in the third month compared to the other treatment modalities. GMI, derived from the term of estimated A1c, had been created to assess more accurately and make more personalized glucose management (24). Tornese et al. (23) investigated the GMI and found that the change in the GMI was insignificant. Seget et al. (25) also published their 2023 study with a significant decrease in the GMI. Unfortunately, numerous studies have indicated that the GMI alone might not be used in this regard. Instead, it is advised to be used with HbA1c value to estimate hypoglycemia risk. An increased gap between HbA1c and GMI is associated with an increased risk of hypoglycemia (25). Moreover, if higher HbA1c values persist despite lower GMI, the risk of diabetes-associated complications will increase (26). Although a larger gap between GMI and HbA1c was observed in the MiniMed™ 780G and MiniMed™ 640G groups initially, it decreased during follow-up in our study. However, in the MDI + CGMs group, this gap persisted over time. HbA1c levels in the MiniMed™ 780G group significantly decreased during follow-up, reaching even lower levels than GMI in the twelfth month. In contrast, in the MiniMed™ 640G group, HbA1c did not differ over time. Considering that lower HbA1c values than GMI and lower HbA1c indicate lower diabetes-associated complications, the MiniMed™ 780G insulin pump is more effective and safe than the MiniMed™ 640G insulin pump and MDI + CGMs in this age group.

The instructions for determining minimum and maximum total daily insulin (TDI) doses are outlined in the MiniMed™ 780G insulin pump manual. The manufacturer has set the minimum TDI at eight daily units (27). In the study by Pulkkinen et al. (22), TDI was a minimum of 8 U/day. In Tornese et al.'s (23) study, the minimum TDI was 6 U initially under manual mode, 6.6 U after auto-mode, and 7.2 U in the 3rd month. In our study, the minimum TDI was under 8 U (4.5 U), initially in manual mode. It reached 8.2 U in the third month and decreased to 7.7 U in the sixth month.

Study Limitations

Low number of patients; more patients are necessary to make more accurate decisions. Retrospective study design.

Conclusion

In our study, we observed that the MiniMed™ 780G was superior to both the MiniMed™ 640G and MDI+CGMs in terms of metabolic control (achieving HbA1c < 7% and TIR > 70%) over a one-year follow-up period in children 2-7 years.

Ethics

Ethics Committee Approval: Ethical committee approval was obtained from the Ethics Committee of the Ege University (decision date: 24.5.1T/24, date: 23.05.2024).

Informed Consent: Informed consent was obtained from all parents or caregivers of children recruited in the study.

Footnotes

Authorship Contributions

Surgical and Medical Practices: Nihal Gül Uslu, Deniz Özalp Kızılay, Günay Demir, Yasemin Atik Altınok, Şükran Darcan, Samim Özen, Damla Gökşen, Concept: Deniz Özalp Kızılay, Şükran Darcan, Samim Özen, Damla Gökşen, Design: Nihal Gül Uslu, Şükran Darcan, Samim Özen, Damla Gökşen, Data Collection or Processing: Nihal Gül Uslu, Günay Demir, Yasemin Atik Altınok, Damla Gökşen, Analysis or Interpretation: Nihal Gül Uslu, Damla Gökşen, Literature Search: Nihal Gül Uslu, Damla Gökşen, Writing: Nihal Gül Uslu, Damla Gökşen.

Conflict of Interest: Two authors of this article, Samim Özen, Damla Gökşen, are members of the Editorial Board of the Journal of Clinical Research in Pediatric Endocrinology. However, they were not involved in any stage of the editorial decision of the manuscript. The editors who evaluated this manuscript are from different institutions.

Financial Disclosure: The authors declared that this study received no financial support.

References

1. Lawrence JM, Divers J, Isom S, Saydah S, Imperatore G, Pihoker C, Marcovina SM, Mayer-Davis EJ, Hamman RF, Dolan L, Dabelea D, Pettitt DJ, Liese AD; SEARCH for Diabetes in Youth Study Group. Trends in prevalence of type 1 and type 2 diabetes in children and adolescents in the US, 2001-2017. *JAMA*. 2021;326:717-727.
2. Dovc K, Boughton C, Tauschmann M, Thabit H, Bally L, Allen JM, Acerini CL, Arnolds S, de Beaufort C, Bergenstal RM, Campbell F, Criego A, Dunger DB, Elleri D, Evans ML, Fröhlich-Reiterer E, Hofer S, Kapellen T, Leelarathna L, Pieber TR, Rami-Merhar B, Shah VN, Sibayan J, Wilinska ME, Hovorka R; APCam11, AP@Home, and KidsAP Consortia. Young children have higher variability of insulin requirements: observations during hybrid closed-loop insulin delivery. *Diabetes Care*. 2019;42:1344-1347. Epub 2019 May 21.
3. American Diabetes Association. 13. Children and Adolescents: Standards of Medical Care in Diabetes-2021. *Diabetes Care*. 2021;44:S180-S199.
4. 2023 SWEET Benchmarking Reports. Available from: <https://www.sweet-project.org/benchmarking-reports.php>
5. Streisand R, Monaghan M. Young children with type 1 diabetes: challenges, research, and future directions. *Curr Diab Rep*. 2014;14:520.
6. Van Name MA, Hilliard ME, Boyle CT, Miller KM, DeSalvo DJ, Anderson BJ, Laffel LM, Woerner SE, DiMeglio LA, Tamborlane WV. Nighttime is the worst time: parental fear of hypoglycemia in young children with type 1 diabetes. *Pediatr Diabetes*. 2018;19:114-120. Epub 2017 Apr 21.
7. Mauras N, Buckingham B, White NH, Tsalikian E, Weinzimer SA, Jo B, Cato A, Fox LA, Aye T, Arbelaez AM, Hershey T, Tansey M, Tamborlane W, Foland-Ross LC, Shen H, Englert K, Mazaika P, Marzelli M, Reiss AL; Diabetes Research in Children Network (DirecNet). Impact of type 1 diabetes in the developing brain in children: a longitudinal study. *Diabetes Care*. 2021;44:983-992. Epub 2021 Feb 10.
8. Desrochers HR, Schultz AT, Laffel LM. Use of diabetes technology in children: role of structured education for young people with diabetes and families. *Endocrinol Metab Clin North Am*. 2020;49:19-35.
9. Ebekozen O, Mungmode A, Sanchez J, Rompicherla S, Demeterco-Berggren C, Weinstock RS, Jacobsen LM, Davis G, McKee A, Akturk HK, Maahs DM, Kamboj MK. Longitudinal trends in glycemic outcomes and technology use for over 48,000 people with type 1 diabetes (2016-2022) from the T1D exchange quality improvement collaborative. *Diabetes Technol Ther*. 2023;25:765-773. Epub 2023 Oct 16.
10. van den Boom L, Karges B, Auzanneau M, Rami-Merhar B, Lienthal E, von Sengbusch S, Datz N, Schröder C, Kapellen T, Laimer M, Schmid SM, Müller H, Wolf J, Holl RW. Temporal trends and contemporary use of insulin pump therapy and glucose monitoring among children, adolescents, and adults with type 1 diabetes between 1995 and 2017. *Diabetes Care*. 2019;42:2050-2056. Epub 2019 Sep 5.
11. Petrovski G, Al Khalaf F, Campbell J, Umer F, Almajaly D, Hamdan M, Hussain K. One-year experience of hybrid closed-loop system in children and adolescents with type 1 diabetes previously treated with multiple daily injections: drivers to successful outcomes. *Acta Diabetol*. 2021;58:207-213. Epub 2020 Oct 12.
12. Abraham MB, de Bock M, Smith GJ, Dart J, Fairchild JM, King BR, Ambler GR, Cameron FJ, McAuley SA, Keech AC, Jenkins A, Davis EA, O'Neal DN, Jones TW; Australian Juvenile Diabetes Research Fund Closed-Loop Research group. Effect of a hybrid closed-loop system on glycemic and psychosocial outcomes in children and adolescents with type 1 diabetes: a randomized clinical trial. *JAMA Pediatr*. 2021;175:1227-1235.
13. Breton MD, Kanapka LG, Beck RW, Ekhlaspour L, Forlenza GP, Cengiz E, Schoelwer M, Ruedy KJ, Jost E, Carria L, Emory E, Hsu LJ, Oliveri M, Kollman CC, Dokken BB, Weinzimer SA, DeBoer MD, Buckingham BA, Chernavsky D, Wadwa RP; iDCL Trial Research Group. A randomized trial of closed-loop control in children with type 1 diabetes. *N Engl J Med*. 2020;383:836-845.
14. Pulkkinen MA, Varimo TJ, Hakonen ET, Harsunen MH, Hyvönen ME, Janér JN, Kiiveri SM, Laakkonen HM, Laakso SM, Wehkalampi K, Hero MT, Miettinen PJ, Tuomaala AK. MiniMed 780G™ in 2- to 6-year-old children: safety and clinical outcomes after the first 12 weeks. *Diabetes Technol Ther*. 2023;25:100-107. Epub 2022 Dec 30.
15. Abraham MB, Smith GJ, Dart J, Davis EA, Jones TW. Clinical outcomes with MiniMed™ 780G advanced hybrid closed-loop therapy in 2- to 6-year-old children with type 1 diabetes. *Diabetes Technol Ther*. 2024;26:341-345. Epub 2024 Mar 8.
16. Annan SF, Higgins LA, Jelleryd E, Hannon T, Rose S, Salis S, Baptista J, Chinchilla P, Marcovecchio ML. ISPAD Clinical Practice Consensus

- Guidelines 2022: Nutritional management in children and adolescents with diabetes. *Pediatr Diabetes*. 2022;23:1297-1321. Epub 2022 Dec 5.
17. Sundberg F, deBeaufort C, Krogvold L, Patton S, Piloya T, Smart C, Van Name M, Weissberg-Benchell J, Silva J, diMeglio LA. ISPAD Clinical Practice Consensus Guidelines 2022: managing diabetes in preschoolers. *Pediatr Diabetes*. 2022;23:1496-1511.
18. Ajjan RA, Cummings MH, Jennings P, Leelarathna L, Rayman G, Wilmot EG. Optimising use of rate-of-change trend arrows for insulin dosing decisions using the FreeStyle Libre flash glucose monitoring system. *Diab Vasc Dis Res*. 2019;16:3-12. Epub 2018 Sep 3.
19. Battelino T, Danne T, Bergenstal RM, Amiel SA, Beck R, Biester T, Bosi E, Buckingham BA, Cefalu WT, Close KL, Cobelli C, Dassau E, DeVries JH, Donaghue KC, Dovc K, Doyle FJ, Garg S, Grunberger G, Heller S, Heinemann L, Hirsch IB, Hovorka R, Jia W, Kordonouri O, Kovatchev B, Kowalski A, Laffel L, Levine B, Mayorov A, Mathieu C, Murphy HR, Nimri R, Nørgaard K, Parkin CG, Renard E, Rodbard D, Saboo B, Schatz D, Stoner K, Urakami T, Weinzimmer SA, Phillip M. Clinical targets for continuous glucose monitoring data interpretation: recommendations from the international consensus on time in range. *Diabetes Care*. 2019;42:1593-1603. Epub 2019 Jun 8.
20. Lendínez-Jurado A, López-Siguero JP, Gómez-Perea A, Ariza-Jiménez AB, Becerra-Paz I, Tapiá-Ceballos L, Cruces-Ponce C, Jiménez-Hinojosa JM, Morcillo S, Leiva-Gea I. Pediatric type 1 diabetes: is age at onset a determining factor in advanced hybrid closed-loop insulin therapy? *J Clin Med*. 2023;12:6951.
21. Beato-Víborá PI, Chico A, Moreno-Fernandez J, Bellido-Castañeda V, Nattero-Chávez L, Picón-César MJ, Martínez-Brocca MA, Giménez-Álvarez M, Aguilera-Hurtado E, Climent-Biescas E, Azriel-Mir S, Rebollo-Román Á, Yoldi-Vergara C, Pazos-Couselo M, Alonso-Carril N, Quirós C. A multicenter prospective evaluation of the benefits of two advanced hybrid closed-loop systems in glucose control and patient-reported outcomes in a real-world setting. *Diabetes Care*. 2024;47:216-224.
22. Pulkkinen MA, Varimo TJ, Hakonen ET, Hero MT, Miettinen PJ, Tuomaala AK. During an 18-month course of automated insulin delivery treatment, children aged 2 to 6 years achieve and maintain a higher time in tight range. *Diabetes Obes Metab*. 2024;26:2431-2438. Epub 2024 Mar 21.
23. Tornese G, Carletti C, Lanzetta MA, Tamaro G, Barbi E, Faleschini E. Safety of real-life usage of advanced hybrid closed-loop system minimed 780G in children with type 1 diabetes younger than 7 years old. *Diabetes Care*. 2023;46:e123-e125.
24. Bergenstal RM, Beck RW, Close KL, Grunberger G, Sacks DB, Kowalski A, Brown AS, Heinemann L, Aleppo G, Ryan DB, Riddlesworth TD, Cefalu WT. Glucose management indicator (GMI): a new term for estimating A1C from continuous glucose monitoring. *Diabetes Care*. 2018;41:2275-2280. Epub 2018 Sep 17.
25. Seget S, Chobot A, Rusak E, Ochab A, Bielawska A, Polanska J, Jarosz-Chobot P. MiniMed 780GTM in children with type 1 diabetes under seven years of age: Prospective open-label, single-arm, double-center, follow-up study. *Technol Health Care*. 2024;32:1463-1472.
26. Gomez-Peralta F, Choudhary P, Cosson E, Irace C, Rami-Merhar B, Seibold A. Understanding the clinical implications of differences between glucose management indicator and glycated haemoglobin. *Diabetes Obes Metab*. 2022;24:599-608. Epub 2022 Feb 8.
27. MiniMed™ Systems Product Specifications; MiniMed™ 780G System Quick Reference Guide, provided by Medtronic. Available from: <https://www.medtronicdiabetes.com/download-library/minimed-780g-system>